NovoEight Market Report 2026

NovoEight Market Overview

• The NovoEight market growth in the historic period has been driven by increasing diagnosis of hemophilia a, availability of recombinant factor viii products • Market expansion is supported by increasing demand for long-acting clotting factors, rising adoption of homecare treatment models • Growth Driver: Rising Prevalence Of Hemophilia Is Driving The Growth Of The Market. • North America was the largest region in 2025.

What Is Covered Under NovoEight Market?

NovoEight refers to turoctocog alfa, which is a recombinant coagulation factor VIII. It is utilized to treat and prevent bleeding in individuals with hemophilia A, a genetic disorder characterized by a deficiency of factor VIII, an essential blood-clotting protein. The main types of indications in novoeight are hemophilia A and surgical procedures. Hemophilia A is a genetic disorder where blood doesn't clot properly due to a lack of clotting factor VIII. It is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and direct sales, catering to various end users such as pediatric, geriatric, hospitals or clinics, and homecare settings.

What Is The NovoEight Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for long-acting clotting factors, rising adoption of homecare treatment models, expanding focus on personalized hemophilia care, growing healthcare investments in rare disease management, increasing patient life expectancy. Major trends in the forecast period include increasing adoption of recombinant coagulation factors, rising focus on prophylactic hemophilia treatment, growing demand for home-based infusion therapies, expansion of personalized bleeding disorder management, enhanced supply chain cold storage capabilities.

Global NovoEight Market Segmentation

1) By Indication: Hemophilia A, Surgical Procedures 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Sales 3) By End User: Adult, Pediatric, Geriatric, Hospitals Or Clinics, Homecare Settings

What Are The Drivers Of The NovoEight Market?

The rising prevalence of hemophilia is expected to propel the growth of the novoeight market going forward. Hemophilia refers to a genetic disorder in which the blood doesn't clot properly, leading to excessive bleeding, even from minor injuries. The rising prevalence of hemophilia is due to improved diagnostic techniques, greater awareness, and better reporting systems, which have led to more individuals being identified and diagnosed with the condition. NovoEight helps individuals with hemophilia effectively control and prevent bleeding episodes, enabling improved clotting function, reducing the risk of spontaneous bleeding, and enhancing overall mobility and quality of life for patients. For instance, in Aoril 2025, according to Pfizer Inc a US-based pharmaceutical and biotechnology corporation, in the 2023/24 period, the UK haemophilia A and B patient population exceeded 11,800 individuals, underscoring a sizable and clinically significant treated population. Therefore, the rising prevalence of hemophilia is driving the growth of the novoeight industry. The rising demand for personalized medicine is expected to propel the growth of the novoeight market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare strategies to individual patients based on their genetic, environmental, and lifestyle factors. The rising demand for personalized medicine is due to advances in genetic research, increased awareness of individualized treatments, and the desire for more effective, targeted therapies that minimize side effects and improve patient outcomes. Novoeight, a recombinant factor VIII therapy, plays a pivotal role in personalized medicine by offering tailored treatment options for patients with hemophilia A, allowing healthcare providers to customize dosing regimens based on individual patient needs, genetic profiles, and response to therapy, ultimately improving treatment outcomes and quality of life. For instance, in February 2024, the Personalized Medicine Coalition, a US-based organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approvals in 2022. Therefore, the rising demand for personalized medicine is driving the growth of the novoeight industry. The increasing healthcare expenditure is expected to propel the growth of the novoeight market going forward. Healthcare expenditure is the total resources spent on healthcare services and goods within a specific region, country, or globally. Healthcare expenditure is increasing due to aging populations, advancements in medical technologies, rising prevalence of chronic diseases, higher patient expectations, and inflation in healthcare service costs. Novoeight is a recombinant factor VIII therapy used for managing hemophilia A and helps reduce healthcare expenditure by minimizing the frequency of bleeding episodes, decreasing the need for emergency interventions, enabling better long-term management of the condition, lowering overall treatment costs, and improving patient quality of life. For instance, in April 2025, according to the Office for National Statistics, a UK-based government agency reported that provisional estimates show UK healthcare spending reached £317 billion in 2024, growing 6.5% nominally and 2.4% in real terms from 2023. Total long-term care expenditure rose 3.1% in real terms in 2023, primarily due to increased government spending. Therefore, the increasing healthcare expenditure is driving the growth of the novoeight industry.

Key Players In The Global NovoEight Market

Major companies operating in the novoeight market are Novo Nordisk A/S

Regional Insights

North America was the largest region in the novoeight market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the NovoEight Market?

The novoeight market consists of sales of novoeight (recombinant factor VIII), novoseven (recombinant factor VII), novoeight [RFVIII] lyophilized powder, and novoeight [RFVIII] prefilled syringe. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the NovoEight Market Report 2026?

The novoeight market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the novoeight industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.